---
schema_version: "secwatch.filing_event.v1"
accession: "0001991792-25-000004"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2025-09-05T23:59:59+00:00"
generated_at: "2026-05-17T08:08:32.959186+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CG Oncology reports 41.8% 24-month CR in Phase 3 BOND-003 for cretostimogene

## Summary
- 24-month CR rate of 41.8% (46/110) in BCG-unresponsive HR NMIBC; 12 additional CRs since April 2025 AUA.
- 90% of 12-month responders remained disease-free at 24 months; 96.6% free from progression to muscle-invasive disease.
- No Grade 3+ TRAEs or deaths; median TRAE resolution 1 day; 97.3% completed all treatments.
- Company plans BLA submission for cretostimogene in HR NMIBC unresponsive to BCG in Q4 2025.

## SEC filing metadata
- accession: 0001991792-25-000004
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2025-09-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000199179225000004/0001991792-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000199179225000004/ck0001991792-20250905.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001991792-25-000004
- JSON: https://secwatch.observer/filing/0001991792-25-000004.json
- Plain text: https://secwatch.observer/filing/0001991792-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.